代谢疾病A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
期刊:Biochemical pharmacology发表年份:2013作者:Vikas K Bhat; Barry D Kerr; Peter R Flatt; Victor A Gault
追踪行业前沿,洞察产业趋势